Abstracts /Lung Cancer 13 (1995) 81-104

tn six of ,he first 25 patients, subsqwnt doses were reduced by 40 mg (one capsule) in all patients. Rest&s: One hundred sixty- two palients were treated 138 with measurable and 24 with assessable disease One hundred two ~a(le”ts were men and 60 women. The mean we was 62 years (range. j6to83,. Tkoverall responw ratewas 14.5%f&at1e”ts wth measurable disease (95% mntidence interval. 9 3% to 21.7%). The median time u) ,rea,m&, failure (IIF) for all pahems war 9 week; The median survival time was 29 weeks; the I-year swvwal rate was 22%. Toxicities included grade 3 or 4 neulrqenia in 40%, which was depcndcnt on the vmorelbine dose. Cnher ,oxiei,~es included mdd 10 moderate naWomiling. diarrhea, and stomatilis. The mean dose m,ew,ty of vinanlbine was 53 mgim’. Conclusron: Oral vinorelbme admininered once weekly an active age”, in stage IV NSCLC Tbe mediansuwival,imcof29weeksis similar,ocha,ach,evedwi,h single- agent intravenous vinorelbine and more aggressive cisplalin-based combinations. Fwther studiaofthwcompound in Ihe palliawe-,n,en, care sntng appear to be indicated.

Early versus late alternating chemotherapy in small-cell lung cmeer Joss RA, Bacchi M. Humy C. Bernhard 1. Ccrny T . Manmclh G c, al Dwaon o, Oncolo~v, “epamnenl o/ h/ed,c,nc, ,V~nrnn~.,p,m,. (‘II- 6OOOLurern 16 Ann Oncol 1995.6.157-66

BockzmunrC From 1984 10 1989. the Swiss Grow for Chmcal Cancer l&arch (SAKK) perfomxd a randomwzd pha& Ill ma1 com- paring early verms late aRemating chemolhcrapy in palwu w,,h small- cell lung cancer. Pot,enbncd,~tetho& 406 ebeible palleMs werccn,cred m,o thetrial. Regimen A mns~stcd of PAV (&PI&. Adnamycm. VP 16-213. and Reeimen B ofCvMOC (Cvclwbos~ham,de. Mcthotrcwe. Oncovm. CCti) Cycles w&c repeated a; rap,dly as posstble Pa,~cn,s were randomized 10 reccwe alher ABABAB (early allcmaung chemolherapy) or AAABBB (late altcrnaling chemolhcrap)) ARcr III cycles patients w,,h lim,,cd disease m complclc or pamal rcm,ss,on and ,hose wlh ex,ens,ve disear I” complclc rem,sston rcccwcd irradiation 10 ,he primary (45 Gy) and ,he CNS (36 Gy). Xsrulfs The overall remission ralc was 87%. w,,h 31% complele rcmissmns The medm suwival of all 406 cbg,hle palicnls was 346 da?s. wtth 15% ol the patients alive a, Iwo years The overall renwsslon raw ,hc rale of complete remiwon. the medtan surwal and Ihc rale of long-,cml survival were not signdicantly d,lTcren, tn the two ,rca,mcn, arms In hm#,ed dwase the eslimalcd percenlages of survival a, 2 years uerc 33% m ,he early and 24% ,n ,he lale altcmalmg chcmothcrap) arms Palicms wth extensive disease survwed wgnificamly longer wilh la,c al,erna,mg chemaherapy dun on Ihe early allema,,~~ rcgmlen (mcdmn sunwal 336 days versus 301 days, p = 0 01) In the latlcr pa,uen,s ,he received dose intensmcs (RDI) ofasplalin. adriamycm and etoposlde were s,gniBcan,ly higher m the late-al,emaUon arm. Patients trcalcd with early al,ema,ing chemotherapy rated ,hcir tuner symp,oms. functional stales, fa,,guc!mala,se and rcstricwn of scaal acwi,y s,gn,ficantly belter. reflectmg an nmprwed subjective adJus,men,. Conclusions: Al,erna,,ra chemolhcrapy w,,h PAV-CV-MOC PIUS cons&dating r&nherapy~s a feasible andelfcnive vca,r&n, for s&II- cell lung cancer. with acceptable to&q. Whereas patients w,h early alternaltng chemotherapy achxve a belter subJecdve adjustment, late al,ema,,ng chemotherapy allows for a higher RDI 01 c,.splatm. adria- mycm and e,opos,de. which resulls m a signi&xUly longer muhan sunwal of paliems w,h extensive dtsease

Effects of swamin on human lung cancer cell lines Rubio GJ. Pine& HU. Wrizueln I, Van Ark-Otre 1. Giaccone G. Deprmrnt o~Onco/ogy. Fmc Unrversq Hosprrol, Amswdam. Eur J Cattar Par, A GenTop 1995;31:244-51.

Swamin cytomxic& was studied in a panel of human lung cancer cell lines bv the MTf assav The concen,ra,mns of swamin wh,ch induad 5&growih inhibition (IQ ranged from 130 10 3715 iM for theaelllinesgmwinginmediumconlaining IO%fe(alcalfserum l.FCS) In only one cell line was the IC.. at a concenlralion lbal can be reached in p&ma of palienu ,rea,ed $,h swamin. Summin was is and 3 3 times more cymtoxic on NCI-N417 cells growing in 2% FCS and in HITES serum-free medium.respectively. lhan growing in 10% FCS No difference in suramin cywtox,city was observed between small and non-small all lung cancer cell lines. Al ,k lower concen,ra,ionr teaed, suramin stimulated proliferation of ,he two small cell lung cancer cell her, NCI-HI87 and NC&N4 17. Of several growth factors Bsted, none Induced s,,mula,ion of grouZh ,n NCI-HI87 and NCI-N417 cell hnes.

“01 did lhey ,n any Way aller Ihe sll~ulal~ry e&l of ~U~XIII~. Cell coun,mg.lDNA flow cytometric analysis and K167 stammg confirmed a h,gher prohferawe swe m suraminexpoved NCI-HIP7 c,clls as compared ,,n,h un,rea,ed cells Howcvcr. topcnsomerase II-G gene expressmn remained unchanged. as assessed by nonhern blo, analysts and immunonammg Suramm had an mhihitory cUea on ,opmsomerax II adwily. as assnsed by ,he kDNA dcacnalion assay, wilh an IC,, of approuma,cly JO iM. In conclusion, suramin has signdican, cymtoxic a~trwty rn a mmonty of human lung cancer cell Imes, and I, stimulales prohlera,mn tn sane mslances The plemtropic action of suramm observed should cawon on the poss,b,li,y of lumwr acceleratmn !n pa,,en,s bemg tread w,h ,h,s drug.

The feasibility of using glycosylated recombinant human rrmukrcvtt cdostvstimubtinr factor fGCSFI to incrust tbe &ntd &e iota& of doxkubicitt; cyelophorphamide and

ttopddt (ACE) in the treammt of small cdl lung cancer Thaicher N, Andcrnon Il. Bbchea NM Girlii DJ, Lallemand G, hlachia D e4 aJ. h4RC Cancer Trials 0~JIce. ~ShaJ?esbuy Road, Camhridnc. Eur JCanxr ht A GenTon 1995~31:1526.

hrtber 5 had A& b&ted, 3 for to&ity and 2 for-progressive disease Of the 71 intewals betwam cycles, 42 (5%) were of the prescribed I4 day& 9 (13%) of 15-20 day& IS (21%) of21 days and fivc(~)bnga,butdurirythcfirslfau~l~36(7~)d47intmals were of 14 days. The main maso” fa sway was haunatological toxicity. All20~e(icntsexpcricnmlWm)~3or4oeuvopcnia,~at2 wrelLFnftcraeyclconly3hsdgadc4andlgde3.17pstientsroquired

mdv=crsc tcactbr~ to G&F was an episode of rash &h fxial &&ma.

tk interval between cycles.

Effect of proton pump inhibitor on cell growth and sensitivity to cir-di~minedichloropl~tinum (II) in non-small cell lung cmetr cell lines Bando T . Kasaham K. Shibara K, Nakatsumi Y. Fujimura M, Matsuda T . Thin, Depm,,en, ,n,en,o, Medicmc. Kannr& Univers,,j School Medtcme, 13-I Takammach,, Kana.nwa 920. Anticaancer Res 1994: 14-2727-30

Recently, the ,mporCance of Ihe potassium pump in the cellular a acculation of cisdiamminedichloropla,inum (II) (CDDP) has been reported. In this study we evahta,ed ihe mle of the proton pump as a detem,hwd of t.he sensitivitv to CDDP in non-small all hnp. cancer cell lines in vitro by using a &edve proron pump inhibitor, A&2000 PC-9 and PC-9/CDDP all lines, which are sensilive or resistant to CDDP. were used for lhese experiments PC-9ICDDP was 17.4-fold more resistant to CDDP lhan PC-9 cells. Relative resisumce was no( allered by coineubation with a non-cywoxic dodge of AG-2000. From these s,u&es, i, was shown that Ihc proton pump inhibitor AG-2000 did no, enhanae the sensitivity ,o CDDP However, as AG-2000 is no, cytotoxic and does rtc4 compromise ule CDDP-se&iv&y m NSCLC cells a, the mmentralion of clinical use for gastroduodenal ulcer. AG- 2000 can be used with CDDP ,n chemcaherapy for lung cancer

A phase II trial of combination chemotherapy with cisplatin

and etoposide in small cell lung cancer Ckon EM. Kim HG. Son T Y , Yuh YJ. Lee SG, Lee CT et al fiptirnen, oflntemal Medicine. KOWJ Cancer Cenler Hospital. Seoul. Tuberc Respir Dis l994;41:632-43

Backgmund: The objective responses of cisplatin and e,opos,de (PVP) mmbination chemotheraw as second-line theraw follotinp. CAV was high (40 -SO%) aed, in se& repon~, PW yield wvival &IS that are al least as gwd as those obtained wi,h cyclophosphamide or doxoruhicin-based regimens and wth less host-related toxicity in chemodwapy-naive patiews We conducted a phase II study ,o evaluae the effect of a combination of cispladn and eloposide as a tim-line